Terence Flynn Analyst PerformanceEquity Research Analyst at Morgan StanleyTerence Flynn is a stock analyst at Morgan Stanley in the medical sector, covering 25 publicly traded companies. Over the past year, Terence Flynn has issued 79 stock ratings, including buy, hold, and sell recommendations. While full access to Terence Flynn's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Terence Flynn's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings115 Last 11 YearsBuy Recommendations50.47% 54 Buy RatingsCompanies Covered25 Unique Companies Ratings Distribution107RatingsDistribution of strong buy, buy, hold, and sell ratings by Terence Flynn.RatingPercentageCount Strong Buy0.0%0 ratings Buy50.5%53 ratings Hold45.8%49 ratings Sell3.7%3 ratingsOut of 107 total stock ratings issued by Terence Flynn at Morgan Stanley, the majority (50.5%) have been Buy recommendations, followed by 45.8% Hold and 3.7% Sell.Best & Worst CallsBest Call0000.0%RCUSMay 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%BHVNMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ60.0% of companies on NASDAQ15 companiesNYSE40.0% of companies on NYSE10 companiesTerence Flynn, an analyst at Morgan Stanley, currently covers 25 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical25 companies100.0%Terence Flynn of Morgan Stanley specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE16 companies64.0%LARGE CAP PHARMA5 companies20.0%MED - DRUGS1 company4.0%MEDICAL SERVICES1 company4.0%HOSPITAL & MEDICAL SERVICE PLANS1 company4.0%PHARMACEUTICAL PREPARATIONS1 company4.0% About Terence FlynnTerence C. Flynn currently works at Morgan Stanley & Co. LLC, as Equity Analyst from 2021. Dr. Flynn also formerly worked at Cytec Industries, Inc., as Research Laboratory Technician, Needham & Co. LLC, as Analyst, Goldman Sachs & Co. LLC, as Analyst from 2010 to 2021, and FM Partners Holdings LLC, as Research Analyst from 2004 to 2009. Dr. Flynn received his doctorate degree from William Marsh Rice University and undergraduate degree from Cornell University.Follow on LinkedIn Terence Flynn's Ratings History at Morgan Stanley Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsBHVNBiohaven5/13/2026Lower Price Target$8.97$18.00Overweight$0.0000.00% ROIRCUSArcus Biosciences5/11/2026Boost Price Target$25.61$22.00Equal Weight$0.0000.00% ROIUTHRUnited Therapeutics5/7/2026Set Price Target$580.95$516.00$0.0000.00% ROIVRTXVertex Pharmaceuticals5/5/2026Boost Price Target$418.09$616.00Overweight$0.0000.00% ROILLYEli Lilly and Company5/1/2026Reiterated Rating$961.47$1,344.00Overweight$0.0000.00% ROIAMGNAmgen5/1/2026Set Price Target$326.04$332.00$0.0000.00% ROIABBVAbbVie4/30/2026Boost Price Target$211.67$278.00Overweight$0.0000.00% ROIAMGNAmgen4/28/2026Boost Price Target$343.85$326.00Equal Weight$0.0000.00% ROINTLAIntellia Therapeutics4/27/2026Boost Price Target$13.22$15.00Equal Weight$0.0000.00% ROIJNJJohnson & Johnson4/15/2026Set Price Target$238.02$283.00$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. RPRXRoyalty Pharma4/10/2026Boost Price Target$47.87$63.00Overweight$0.0000.00% ROIUTHRUnited Therapeutics4/10/2026Boost Price Target$569.04$519.00Equal Weight$0.0000.00% ROIVRTXVertex Pharmaceuticals4/10/2026Boost Price Target$437.02$612.00Overweight$0.0000.00% ROIBNTXBioNTech4/10/2026Boost Price Target$93.13$126.00Overweight$0.0000.00% ROIAMGNAmgen4/10/2026Boost Price Target$354.48$326.00Equal Weight$0.0000.00% ROILLYEli Lilly and Company4/10/2026Boost Price Target$939.18$1,327.00Overweight$0.0000.00% ROIPFEPfizer4/10/2026Boost Price Target$27.02$28.00Equal Weight$0.0000.00% ROIJNJJohnson & Johnson4/10/2026Boost Price Target$239.90$267.00Overweight$0.0000.00% ROIALMSAlumis3/20/2026Boost Price Target$25.38$38.00Overweight$0.0000.00% ROIJNJJohnson & Johnson3/18/2026Set Price Target$237.17$253.00$0.0000.00% ROIJNJJohnson & Johnson3/18/2026Reiterated Rating$237.60Overweight$0.0000.00% ROIPFEPfizer3/17/2026Set Price Target$27.10$27.00Positive$0.0000.00% ROIBNTXBioNTech3/10/2026Lower Price Target$83.60$125.00Overweight$0.0000.00% ROIVRTXVertex Pharmaceuticals3/10/2026Boost Price Target$499.41$596.00Overweight$0.0000.00% ROILLYEli Lilly and Company3/5/2026Reiterated Rating$986.00$1,313.00Overweight$0.0000.00% ROIVRTXVertex Pharmaceuticals2/13/2026Reiterated Rating$495.48$570.00Overweight$0.0000.00% ROIRPRXRoyalty Pharma2/12/2026Reiterated Rating$44.23$61.00Overweight$0.0000.00% ROIBIIBBiogen2/8/2026Set Price Target$201.18$190.00$0.0000.00% ROIBMYBristol Myers Squibb2/6/2026Reiterated Rating$61.43$40.00Underweight$0.0000.00% ROIABBVAbbVie2/5/2026Boost Price Target$217.04$270.00Overweight$0.0000.00% ROILLYEli Lilly and Company2/5/2026Boost Price Target$1,107.13$1,313.00Overweight$0.0000.00% ROIAMGNAmgen2/4/2026Boost Price Target$338.59$309.00Equal Weight$0.0000.00% ROIJNJJohnson & Johnson1/22/2026Boost Price Target$219.82$200.00Equal Weight$0.0000.00% ROIRCUSArcus Biosciences1/8/2026Reiterated Rating$23.19$20.00Equal Weight$0.0000.00% ROINRIXNurix Therapeutics1/8/2026Set Price Target$18.49$36.00Overweight$0.0000.00% ROIALMSAlumis1/7/2026Boost Price Target$16.23$33.00Overweight$0.0000.00% ROIBHVNBiohaven1/6/2026Lower Price Target$9.47$21.00Overweight$0.0000.00% ROIJNJJohnson & Johnson12/12/2025Boost Price Target$210.42$197.00Equal Weight$0.0000.00% ROIPFEPfizer12/12/2025Lower Price Target$25.90$28.00Equal Weight$0.0000.00% ROIBMYBristol Myers Squibb12/12/2025Reiterated Rating$51.16$37.00Underweight$0.0000.00% ROINobody Understands Why Trump Is Invading Iran (here’s the answer) (Ad)Most investors are reacting to the Iran strikes without understanding the underlying motive driving the decision. Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there is a hidden reason behind the bombing - and knowing it could change how you position your money right now.Discover the real reason behind the Iran strikes before markets reactGPCRStructure Therapeutics12/12/2025Boost Price Target$66.60$125.00Overweight$0.0000.00% ROIBIIBBiogen12/12/2025Boost Price Target$173.12$156.00Equal Weight$0.0000.00% ROIAMGNAmgen12/12/2025Lower Price Target$315.74$304.00Equal Weight$0.0000.00% ROIABBVAbbVie12/12/2025Boost Price Target$222.00$269.00Overweight$0.0000.00% ROIMRKMerck & Co., Inc.12/12/2025Boost Price Target$99.54$102.00Equal Weight$0.0000.00% ROIVRTXVertex Pharmaceuticals12/5/2025Set Price Target$461.18$564.00$0.0000.00% ROIVRTXVertex Pharmaceuticals12/3/2025Upgrade$433.15$516.00Overweight$0.0000.00% ROIMRKMerck & Co., Inc.12/2/2025Boost Price Target$100.74$120.00Buy$0.0000.00% ROILLYEli Lilly and Company11/24/2025Boost Price Target$1,058.05$1,290.00Overweight$0.0000.00% ROIBHVNBiohaven11/18/2025Lower Price Target$9.58$26.00Overweight$0.0000.00% ROILLYEli Lilly and Company11/13/2025Boost Price Target$1,018.28$1,171.00Overweight$0.0000.00% ROIOGNOrganon & Co.11/11/2025Lower Price Target$7.73$9.00Equal Weight$0.0000.00% ROIBHVNBiohaven11/5/2025Reiterated Rating$8.42Overweight$0.0000.00% ROIAMGNAmgen11/5/2025Lower Price Target$296.70$329.00Equal Weight$0.0000.00% ROIBNTXBioNTech11/3/2025Reiterated Rating$103.96$134.00Overweight$0.0000.00% ROIMRKMerck & Co., Inc.11/3/2025Boost Price Target$83.42$100.00Equal Weight$0.0000.00% ROIJNJJohnson & Johnson10/15/2025Set Price Target$190.88$190.00$0.0000.00% ROINRIXNurix Therapeutics10/14/2025Lower Price Target$9.17$15.00Equal Weight$0.0000.00% ROIPFEPfizer10/10/2025Lower Price Target$25.08$32.00Equal Weight$0.0000.00% ROIRPRXRoyalty Pharma10/10/2025Lower Price Target$36.06$54.00Overweight$0.0000.00% ROIBNTXBioNTech10/10/2025Lower Price Target$104.48$131.00Overweight$0.0000.00% ROIUTHRUnited Therapeutics10/10/2025Boost Price Target$443.68$435.00Equal Weight$0.0000.00% ROIJNJJohnson & Johnson10/10/2025Boost Price Target$191.29$178.00Equal Weight$0.0000.00% ROILLYEli Lilly and Company10/3/2025Lower Price Target$820.69$1,023.00Overweight$0.0000.00% ROIALMSAlumis8/15/2025Lower Price Target$4.39$22.00Overweight$0.0000.00% ROIBHVNBiohaven8/12/2025Lower Price Target$13.42$54.00Overweight$0.0000.00% ROIPFEPfizer8/6/2025Boost Price Target$23.96$33.00Equal Weight$0.0000.00% ROIAMGNAmgen8/6/2025Boost Price Target$284.41$333.00Equal Weight$0.0000.00% ROIABBVAbbVie8/1/2025Boost Price Target$193.55$255.00Overweight$0.0000.00% ROIBMYBristol Myers Squibb7/31/2025Reiterated Rating$43.37Hold$0.0000.00% ROIJNJJohnson & Johnson7/17/2025Boost Price Target$164.78$176.00Equal Weight$0.0000.00% ROINRIXNurix Therapeutics7/15/2025Set Price Target$12.69$16.00Equal Weight$0.0000.00% ROIRPRXRoyalty Pharma7/10/2025Boost Price Target$36.18$54.00Overweight$0.0000.00% ROIBNTXBioNTech7/10/2025Boost Price Target$112.29$133.00Overweight$0.0000.00% ROILLYEli Lilly and Company7/10/2025Reiterated Rating$792.63$1,135.00Overweight$0.0000.00% ROIMRKMerck & Co., Inc.7/10/2025Lower Price Target$84.40$98.00Equal Weight$0.0000.00% ROIJNJJohnson & Johnson7/10/2025Boost Price Target$157.81$171.00Equal Weight$0.0000.00% ROIBMYBristol Myers Squibb7/10/2025Lower Price Target$48.17$34.00Underweight$0.0000.00% ROIUTHRUnited Therapeutics7/10/2025Lower Price Target$301.15$328.00Equal Weight$0.0000.00% ROIARVNArvinas5/9/2025Lower Price Target$6.69$11.00Equal Weight$00.0000.00% ROIRCUSArcus Biosciences5/9/2025Lower Price Target$8.46$22.00Overweight$00.0000.00% ROIBNTXBioNTech5/6/2025Lower Price Target$99.33$132.00Overweight$00.0000.00% ROIOGNOrganon & Co.5/5/2025Lower Price Target$8.82$10.00Equal Weight$00.0000.00% ROIUTHRUnited Therapeutics5/1/2025Boost Price Target$296.52$348.00Equal Weight$000.0000.00% ROIABBVAbbVie4/28/2025Boost Price Target$185.96$250.00Overweight$000.0000.00% ROIJNJJohnson & Johnson4/16/2025Boost Price Target$154.80$169.00Equal Weight$000.0000.00% ROIOGNOrganon & Co.4/9/2025Lower Price Target$11.32$15.00Equal Weight$0.0000.00% ROILLYEli Lilly and Company4/9/2025Lower Price Target$702.91$1,124.00Overweight$000.0000.00% ROIJNJJohnson & Johnson4/9/2025Boost Price Target$146.25$164.00Equal Weight$000.0000.00% ROIABBVAbbVie4/9/2025Boost Price Target$167.66$241.00Overweight$000.0000.00% ROISpaceX eyes a 1.75 trillion valuation - here's what to know (Ad)Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.See how to get positioned in SpaceX before the announcement goes publicAMGNAmgen4/9/2025Boost Price Target$272.28$330.00Equal Weight$000.0000.00% ROIARVNArvinas3/13/2025Lower Price Target$8.58$12.00Equal Weight$00.0000.00% ROIBNTXBioNTech3/11/2025Lower Price Target$100.97$139.00Overweight$00.0000.00% ROIBHVNBiohaven3/7/2025Lower Price Target$30.08$63.00Overweight$0.0000.00% ROIRCUSArcus Biosciences2/18/2025Lower Price Target$11.00$25.00Overweight$00.0000.00% ROICRSPCRISPR Therapeutics2/14/2025Boost Price Target$43.49$32.00Underweight$00.0000.00% ROIOGNOrganon & Co.2/14/2025Lower Price Target$16.17$16.00Equal Weight$0.0000.00% ROIMRKMerck & Co., Inc.2/5/2025Lower Price Target$90.99$106.00Equal Weight$000.0000.00% ROINRIXNurix Therapeutics2/3/2025Boost Price Target$19.71$17.00Equal Weight$00.0000.00% ROIABBVAbbVie2/3/2025Boost Price Target$188.39$239.00Overweight$000.0000.00% ROINTLAIntellia Therapeutics1/27/2025Downgrade$10.99$11.00Equal Weight$00.0000.00% ROIJNJJohnson & Johnson1/23/2025Lower Price Target$146.82$163.00Equal Weight$000.0000.00% ROIMRKMerck & Co., Inc.1/21/2025Lower Price Target$96.46$113.00Equal Weight$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James FinancialBMO Capital Markets Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
